William J. Burns's most recent trade in Agios Pharmaceuticals Inc was a trade of 6,000 Performance share units done . Disclosure was reported to the exchange on June 24, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2025 | 6,000 | 6,000 | - | - | Performance share units | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2025 | 6,000 | 31,449 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 33.54 per share. | 24 Jun 2025 | 2,799 | 28,650 (0%) | 0% | 33.5 | 93,878 | Common stock |
| Zebra Tech | William J. Burns | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2025 | 5,463 | 0 | - | - | Stock Appreciation Right | |
| Zebra Tech | William J. Burns | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 149.57 per share. | 07 May 2025 | 2,284 | 48,080 (0%) | 0% | 149.6 | 341,618 | Class A Common Stock |
| Zebra Tech | William J. Burns | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 257.10 per share. | 07 May 2025 | 1,167 | 46,913 (0%) | 0% | 257.1 | 300,036 | Class A Common Stock |
| Oshkosh Corp | William J. Burns | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2025 | 1,927 | 3,210 (0%) | 0% | 0 | Common Stock | |
| Zebra Tech | William J. Burns | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 255.95 per share. | 02 May 2025 | 2,005 | 46,802 (0%) | 0% | 256.0 | 513,180 | Class A Common Stock |
| Zebra Tech | William J. Burns | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 249.97 per share. | 02 May 2025 | 1,006 | 45,796 (0%) | 0% | 250.0 | 251,470 | Class A Common Stock |
| Cross Country Healthcares,... | William J. Burns | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.89 per share. | 31 Mar 2025 | 5,655 | 242,508 (0%) | 0% | 14.9 | 84,203 | Common Stock |
| Cross Country Healthcares,... | William J. Burns | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.89 per share. | 31 Mar 2025 | 2,891 | 248,163 (0%) | 0% | 14.9 | 43,047 | Common Stock |
| Cross Country Healthcares,... | William J. Burns | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.89 per share. | 31 Mar 2025 | 2,496 | 253,477 (0%) | 0% | 14.9 | 37,165 | Common Stock |
| Cross Country Healthcares,... | William J. Burns | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.89 per share. | 31 Mar 2025 | 2,423 | 251,054 (0%) | 0% | 14.9 | 36,078 | Common Stock |
| Cross Country Healthcares,... | William J. Burns | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2025 | 14,373 | 255,973 (0%) | 0% | 0 | Common Stock | |
| Zebra Tech | William J. Burns | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 306.84 per share. | 04 Mar 2025 | 14,340 | 48,807 (0%) | 0% | 306.8 | 4,400,086 | Class A Common Stock |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 43,500 | 43,500 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 12,000 | 12,000 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 11,759 | 11,759 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 11,333 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 27,130 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 4,000 | 4,000 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 4,000 | 22,650 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 3,833 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 3,833 | 19,787 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,681 | 25,449 (0%) | 0% | 35.5 | 59,743 | Common stock |
| Zebra Tech | William J. Burns | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 315.05 per share. | 01 Mar 2025 | 1,548 | 34,467 (0%) | 0% | 315.0 | 487,697 | Class A Common Stock |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,187 | 21,463 (0%) | 0% | 35.5 | 42,186 | Common stock |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,137 | 18,650 (0%) | 0% | 35.5 | 40,409 | Common stock |
| Zebra Tech | William J. Burns | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 978 | 36,015 (0%) | 0% | 0 | Class A Common Stock | |
| Zebra Tech | William J. Burns | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 409.32 per share. | 07 Dec 2024 | 401 | 35,037 (0%) | 0% | 409.3 | 164,137 | Class A Common Stock |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 52.00 per share. | 07 Nov 2024 | 13,411 | 24,041 (0%) | 0% | 52 | 697,372 | Common stock |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 52.56 per share. | 07 Nov 2024 | 8,341 | 15,700 (0%) | 0% | 52.6 | 438,403 | Common stock |
| Oshkosh Corp | William J. Burns | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jul 2024 | 1,266 | 1,266 (0%) | 0% | 0 | Common Stock | |
| Zebra Tech | William J. Burns | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2024 | 7,709 | 0 | - | - | Stock Appreciation Right | |
| Zebra Tech | William J. Burns | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 98.87 per share. | 09 May 2024 | 5,321 | 38,155 (0%) | 0% | 98.9 | 526,087 | Class A Common Stock |
| Zebra Tech | William J. Burns | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 319.30 per share. | 09 May 2024 | 2,717 | 35,438 (0%) | 0% | 319.3 | 867,538 | Class A Common Stock |
| Zebra Tech | William J. Burns | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 315.79 per share. | 05 May 2024 | 811 | 32,834 (0%) | 0% | 315.8 | 256,106 | Class A Common Stock |
| Zebra Tech | William J. Burns | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 309.59 per share. | 05 May 2024 | 556 | 33,645 (0%) | 0% | 309.6 | 172,132 | Class A Common Stock |
| Zebra Tech | William J. Burns | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 309.05 per share. | 02 May 2024 | 12,943 | 34,201 (0%) | 0% | 309.0 | 4,000,034 | Class A Common Stock |
| Cross Country Healthcares,... | William J. Burns | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2024 | 22,036 | 258,307 (0%) | 0% | 0 | Common Stock | |
| Cross Country Healthcares,... | William J. Burns | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.72 per share. | 31 Mar 2024 | 7,308 | 250,999 (0%) | 0% | 18.7 | 136,806 | Common Stock |
| Cross Country Healthcares,... | William J. Burns | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.72 per share. | 31 Mar 2024 | 4,479 | 246,520 (0%) | 0% | 18.7 | 83,847 | Common Stock |
| Cross Country Healthcares,... | William J. Burns | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.72 per share. | 31 Mar 2024 | 2,496 | 244,024 (0%) | 0% | 18.7 | 46,725 | Common Stock |
| Cross Country Healthcares,... | William J. Burns | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.72 per share. | 31 Mar 2024 | 2,424 | 241,600 (0%) | 0% | 18.7 | 45,377 | Common Stock |
| Cross Country Healthcares,... | William J. Burns | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 18,573 | 236,271 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 60,000 | 60,000 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 17,000 | 17,000 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 4,000 | 8,000 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 4,000 | 38,518 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 3,834 | 3,833 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 3,834 | 35,811 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 32.57 per share. | 01 Mar 2024 | 1,349 | 37,169 (0%) | 0% | 32.6 | 43,937 | Common stock |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 32.57 per share. | 01 Mar 2024 | 1,293 | 34,518 (0%) | 0% | 32.6 | 42,113 | Common stock |
| Agios Pharmaceuticals Inc | William James Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 1,833 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Burns James William | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 1,833 | 32,211 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Burns James William | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 25.14 per share. | 12 Feb 2024 | 545 | 31,666 (0%) | 0% | 25.1 | 13,701 | Common stock |
| Agios Pharmaceuticals Inc | William Burns James | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 5,750 | 32,086 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | James Burns William | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 5,750 | 0 | - | - | Performance share units | |
| Agios Pharmaceuticals Inc | William James Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 21.64 per share. | 20 Jan 2024 | 1,708 | 30,378 (0%) | 0% | 21.6 | 36,961 | Common stock |
| Agios Pharmaceuticals Inc | William James Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 3,250 | 0 | - | - | Performance share units | |
| Agios Pharmaceuticals Inc | James Burns William | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 3,250 | 27,499 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | James Burns William | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 22.99 per share. | 05 Jan 2024 | 1,163 | 26,336 (0%) | 0% | 23.0 | 26,737 | Common stock |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 26.28 per share. | 17 Aug 2023 | 6,395 | 23,890 (0%) | 0% | 26.3 | 168,061 | Common stock |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 5,750 | 5,750 | - | - | Performance share units | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 5,750 | 31,992 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 28.36 per share. | 28 Jun 2023 | 1,707 | 30,285 (0%) | 0% | 28.4 | 48,411 | Common stock |
| Cross Country Healthcares,... | William J. Burns | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 18,482 | 263,501 (0%) | 0% | 0 | Common Stock | |
| Cross Country Healthcares,... | William J. Burns | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.32 per share. | 31 Mar 2023 | 15,310 | 248,191 (0%) | 0% | 22.3 | 341,719 | Common Stock |
| Cross Country Healthcares,... | William J. Burns | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.32 per share. | 31 Mar 2023 | 8,517 | 239,674 (0%) | 0% | 22.3 | 190,099 | Common Stock |
| Cross Country Healthcares,... | William J. Burns | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.32 per share. | 31 Mar 2023 | 4,479 | 235,195 (0%) | 0% | 22.3 | 99,971 | Common Stock |
| Cross Country Healthcares,... | William J. Burns | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.32 per share. | 31 Mar 2023 | 2,497 | 232,698 (0%) | 0% | 22.3 | 55,733 | Common Stock |
| Cross Country Healthcares,... | William J. Burns | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 38,908 | 245,019 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 44,000 | 44,000 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 12,000 | 12,000 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 3,833 | 27,371 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 3,833 | 7,667 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.02 per share. | 01 Mar 2023 | 1,129 | 26,242 (0%) | 0% | 25.0 | 28,248 | Common stock |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 1,738 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 1,738 | 24,147 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.91 per share. | 14 Feb 2023 | 609 | 23,538 (0%) | 0% | 28.9 | 17,606 | Common stock |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,834 | 23,052 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,834 | 1,833 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.44 per share. | 10 Feb 2023 | 643 | 22,409 (0%) | 0% | 28.4 | 18,287 | Common stock |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2022 | 8,750 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2022 | 8,750 | 23,815 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.48 per share. | 23 Dec 2022 | 2,597 | 21,218 (0%) | 0% | 28.5 | 73,963 | Common stock |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 41,000 | 41,000 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 11,500 | 11,500 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 724 | 15,008 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 724 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.08 per share. | 22 Feb 2022 | 215 | 14,793 (0%) | 0% | 29.1 | 6,252 | Common stock |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 5,250 | 16,439 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 5,250 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.50 per share. | 14 Feb 2022 | 2,155 | 14,284 (0%) | 0% | 30.5 | 65,728 | Common stock |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 1,738 | 1,738 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 1,738 | 11,189 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 1,833 | 3,667 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 1,833 | 10,094 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | James William Burns | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.42 per share. | 10 Feb 2022 | 643 | 9,451 (0%) | 0% | 31.4 | 20,206 | Common stock |